Novimmune Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
MRUS | C | Merus N.V. | 0.74 | |
TAK | C | Takeda Pharmaceutical Company Limited | 0.14 |
Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
PPH | D | Market Vectors Pharmaceutical ETF | 4.43 | |
SBIO | B | ALPS Medical Breakthroughs ETF | 2.38 | |
OZEM | D | Roundhill GLP-1 & Weight Loss ETF | 1.96 | |
GINX | D | SGI Enhanced Global Income ETF | 1.74 | |
CANC | C | Tema Oncology ETF | 1.42 |
Compare ETFs
- Novimmune
Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998.Novimmune has six publicly disclosed drug in their pipeline:
NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017.
NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.
NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016.
NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.
NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers.
NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors.No drugs have been approved as of yet.
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles